Fundraising Fox
Adaxion Therapeutics
Founded 2022 · 24 employees on LinkedIn · 2 known investors
Find your way into Adaxion Therapeutics
Sign up to see every warm intro you have to Adaxion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adaxion Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses. The company focuses on enabling biotherapeutics that would otherwise face prohibitive immunogenicity.
Investors · 2
Frequently asked questions
- What does Adaxion Therapeutics do?
- ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses. The company focuses on enabling biotherapeutics that would otherwise face prohibitive immunogenicity.
- Who are Adaxion Therapeutics's investors?
- Adaxion Therapeutics's investors include JDRF T1D Fund, Vivo Capital.